StockData
Becton Dickinson & Co logo

Becton Dickinson & Co

BDXNYSESurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 8/30
$190.74−1.01 (-0.53%)

Close on Oct 19, 2026Market cap $52.48BP/E 57.6Yield 2.18%

Becton Dickinson Cumulative Registered Clinical Studies by Year

Cumulative Registered Clinical Studies — BD & C.R. Bard

Periods

Becton Dickinson Cumulative Registered Clinical Studies: 90 in FY2026, up 12.5% from a year earlier. That is the highest of the 12 years on record here.

Latest, FY2026
90
Period ended Sep 30, 2026 (CY2026)
Change on a year earlier
+12.5%
80 in FY2025
History
12 years
Since FY2015
Sources
1
NIH ClinicalTrials.gov Registry — Becton Dickinson & C.R. Bard

Where the FY2026 figure comes from

Source: NIH ClinicalTrials.gov Registry — Becton Dickinson & C.R. Bard ↗

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Becton Dickinson Cumulative Registered Clinical Studies, annual FY2015–FY2026 [Data set]. Compiled from Becton Dickinson SEC filings and investor materials. https://stockdatahq.com/stocks/bdx/kpis/ext-ct-cum

See every metric in the Becton Dickinson KPI table. Data updated Nov 7, 2026.

See a number that looks wrong?